REDWOOD CITY,
Calif.—Protein engineering company Codexis Inc. will now offer high-performance enzymes for
customers using next-generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in-vitro molecular diagnostic applications, the
company reported recently. The first such proprietary enzyme will target improved library prep for NGS users, with expected availability in beta-test format
by Q2 2017.

“Enzymes are critical to the sensitivity and reliability of NGS and PCR analyses,” Michael
Aldridge, senior vice president of Corporate & Strategic Development at Codexis, commented in a statement. “Historically, NGS and PCR work-flows
relied on only modestly engineered enzymes. However, as users push NGS and PCR into new, more demanding applications, such as liquid biopsy and personalized
medicine samples, more capable enzymes are required.”